Physician profile
Ding M Ma
NPI 1699031005
$4,554.47
in general payments reported to CMS, 2019-2025
24 companies · $471 in 2025
The $471 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,226 · 2020: $663 · 2021: $763 · 2022: $679 · 2023: $409 · 2024: $344 · 2025: $471.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,207 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,206.62 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb, A Division of Bausch Health US, LLC | $652.19 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $539.05 | 2019-2025 | Cequa |
| Allergan, INC. | $420.95 | 2019-2022 | |
| Kala Pharmaceuticals, INC. | $333.96 | 2019-2022 | |
| Abbvie INC. | $330.76 | 2022-2025 | |
| Alcon Vision LLC | $329.12 | 2020-2023 | Rocklatan, Rhopressa, Simbrinza |
| Eyevance Pharmaceuticals LLC | $292.19 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $254.97 | 2019-2023 | |
| Bausch & Lomb Americas INC. | $223.55 | 2022-2025 | Xiidra, Miebo, Vyzulta |
| Tarsus Pharmaceuticals, INC. | $208.86 | 2024-2025 | Xdemvy |
| Shire North American Group INC | $201.45 | 2019 | |
| Mallinckrodt Hospital Products INC. | $143.11 | 2024-2025 | Acthar |
| Johnson & Johnson Surgical Vision, INC. | $141.55 | 2019-2023 | Tecnis Simplicity |
| Regeneron Healthcare Solutions, INC. | $127.84 | 2019-2020 | |
| Oyster Point Pharma, INC. | $82.57 | 2022-2024 | Tyrvaya, Ryzumvi |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $71.86 | 2025 | Tepezza |
| Aerie Pharmaceuticals, INC. | $43.68 | 2020-2021 | |
| Johnson & Johnson Vision Care, INC. | $28.96 | 2019-2020 | |
| Rayner Intraocular Lenses Limited | $26.18 | 2025 | Rayner Cataract Set 1, Rayone Emv, Rayone Aspheric |
| Glaxosmithkline, LLC. | $23.94 | 2025 | Ojjaara |
| Dompe US, INC. | $22.89 | 2025 | Oxervate |
| Optos, INC. | $21.52 | 2019 | |
| Merz Pharmaceuticals, LLC | $19.25 | 2025 | Xeomin |
| Akorn, INC. | $14.07 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ding Ma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.